AbbVie Inc. expects its neuroscience franchise to generate $12.7 billion [1] in sales during the current fiscal year.
This growth signals a strategic shift for the North Chicago-based company as it diversifies its revenue streams. By expanding its footprint in neuroscience, AbbVie reduces its reliance on older legacy products while tapping into high-demand medical markets.
Management said the positive outlook is due to a strong drug pipeline and the impact of recent product launches [1, 2]. These developments have allowed the company to scale its operations and reach a broader patient base globally.
Recent financial data shows the franchise is already gaining momentum. AbbVie reported neuroscience sales of $6.1 billion [3] during the first half of 2026.
This figure represents a year-over-year growth rate of 21.8 percent [3] for the first half of the year. The surge suggests that new treatments are seeing rapid adoption among healthcare providers and patients.
The company continues to invest in the development of new therapies to maintain this trajectory. The current projections rely on the continued performance of these new launches through the end of the fiscal period [1, 2].
“AbbVie expects its neuroscience franchise to generate $12.7 billion in sales this fiscal year.”
The rapid expansion of AbbVie's neuroscience division indicates a broader industry trend toward specialized neurological treatments. By securing a multi-billion dollar revenue stream in this sector, AbbVie is positioning itself to offset potential revenue cliffs from patent expirations in other areas of its portfolio.
